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Abstract 
Alzheimer’s disease (AD) is partially characterized by excessive accumulation of amyloid-b 
(Ab) in the brain. Ab oligomers have greater toxicity than Ab fibrils and induce neuronal 
stress. The Integrated Stress Response (ISR) is activated in response to cellular stress and 
increases expression of activating transcription factor 4 (ATF4) and its target genes. 
Prolonged activation has been shown to induce aberrant cell death, and increased markers of 
the ISR have been found in the brains of AD patients. However, the exact mechanism of 
amyloid-b-induced death is largely unknown. We aimed to determine if Ab-induced neuronal 
death occurs through ATF4-mediated upregulation of its downstream pro-apoptotic gene 
PUMA. Primary cortical neurons were treated with Ab oligomers. Ab induced apoptosis in a 
PUMA-dependent manner in the presence of ATF4. These results suggest that therapeutics 
targeting ATF4 and PUMA may be successful in alleviating excessive neuronal death 
induced by amyloid-b in Alzheimer’s disease. 
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Lay Summary 
Alzheimer’s disease (AD) is the most common type of dementia. AD is a degenerative 
disease affecting the brain. As the disease progresses, brain cells continually. One of the 
main proteins that is involved in the development of AD is amyloid-b. When levels of 
amyloid-b are elevated in the brain, the proteins tend to aggregate together. These clumps are 
harmful to brain cells, which are also called neurons. Amyloid-b can cause high levels of 
stress in neurons. The Integrated Stress Response (ISR) is a pathway within cells that helps 
them to overcome a wide range of stress signals. When the ISR detects stress in the 
environment, it becomes activated and increases the expression of another protein called 
Activating Transcription Factor 4 (ATF4). ATF4 helps increase the production of proteins 
that can help the cell mediate the stress and return back to normal. However, sustained 
activation of the ISR has been shown to promote death signals within cells. High levels of 
many ISR proteins have been found in the brains of AD patients. The way in which amyloid-
b causes neuronal death remains largely unknown. We aimed to determine if amyloid-b 
causes neuronal death through prolonged activation of ATF4 and increased expression of the 
pro-death protein PUMA. In the present study, neurons were treated with amyloid-b 
aggregates. Amyloid-b induced neuronal death in the presence of both ATF4 and PUMA. 
When ATF4 or PUMA were removed from these neurons, amyloid-b did not cause death. 
The results suggest that drugs targeting ATF4 and PUMA may be successful in reducing 
neuronal death caused by amyloid-bin Alzheimer’s disease.  
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Chapter 1  
1 Introduction 
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia (Chambers, Bancej, & 
McDowell, 2016). It is characterized by a progressive loss in hippocampal and total brain 
mass, coupled with increasing memory loss and behavioural changes, that can ultimately 
result in death (Nelson, Braak, & Markesbery, 2009). Currently, it is estimated that close 
to 600,000 Canadians live with dementia (Chambers et al., 2016). Caring for those with 
AD poses a large financial burden on our healthcare system, with annual costs close to 
$10 billion (Chambers et al., 2016). With an aging population, these numbers will only 
rise, which highlights the relevance of dementia research.  
One of the most common behavioural symptoms of Alzheimer’s disease is memory 
impairment that affects daily functioning. It is often the earliest manifestation of the 
disease that is noticed by patients and their families. Other behavioural symptoms include 
difficulties with language and changes in personality (Chambers et al., 2016). 
Pathologically, AD is characterized by two main hallmarks: amyloid plaques and 
neurofibrillary tangles. Amyloid plaques are composed of extracellular aggregates of 
amyloid-b protein. Neurofibrillary tangles are composed of hyperphosphorylated tau 
protein that has aggregated intracellularly (Joshi, Kornfeld, & Mochly-Rosen, 2016; 
Nelson et al., 2009).  
In Alzheimer’s disease, pathological changes occur prior to the development of clinical 
symptoms. Pathology generally begins in the entorhinal cortex (EC) in the temporal lobe, 
progresses through the limbic system, and gradually spreads throughout the cortex (Braak 
& Braak, 1991; Masliah et al., 1994). The entorhinal cortex has synaptic connections 
with structures such as the hippocampus, which highlights its importance as a hub for 
Alzheimer’s disease progression (Harris et al., 2010). The hippocampus is a structure that 
is important for memory, and correlations between hippocampal volume and cognitive 
testing scores in AD patients have been established (Farrow et al., 2007). More 
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specifically, in early AD, smaller hippocampal volumes correlated with worse 
performance on cognitive tests. In addition to volumetric differences, decreased synapse 
numbers in the EC and hippocampus have been found in patients with early Alzheimer’s 
disease compared to mild cognitive impairment and normal aging (Scheff, Price, Schmitt, 
& Mufson, 2006). This lowered number of synapses was correlated with lower cognitive 
testing scores.  
1.1.1 Amyloid-b 
Amyloid-b (Ab) peptide is generated from the sequential proteolytic cleavage of the 
amyloid precursor protein (APP; Chen et al., 2017; Kang et al., 1987). APP is located on 
the plasma membrane and contains a single transmembrane domain, along with an 
intracellular C-terminus and a large extracellular N-terminus (Figure 1.1). It can be 
processed through two proteolytic pathways: a non-amyloidogenic pathway and an 
amyloidogenic pathway (Chen et al., 2017; Kang et al., 1987; Selkoe, 1994).The non-
amyloidogenic pathway occurs when APP is first cleaved by a-secretase, which releases 
the N-terminus into the extracellular environment. The cleavage site for a-secretase lies 
within the amyloid-b sequence, and thus prevents pathologic amyloid-b production. The 
membrane-bound C-terminus (CTFa) is subsequently cleaved by g-secretase, which then 
releases extracellular P3 and APP intracellular domain (AICD; Chen et al., 2017; Olsson 
et al., 2014). For processing through the amyloidogenic pathway, APP is cleaved by b-
secretase, also termed b-site APP cleaving enzyme (BACE1). Cleavage by b-secretase 
releases the extracellular N-terminal fragment and leaves the membrane-tethered C-
terminal fragment (CTFb). CTFb is subsequently cleaved by g-secretase to generate 
AICD and amyloid-b peptide (Murphy & Levine, 2010; Olsson et al., 2014). g-secretase 
can cleave CTFb at many different sites, generating amyloid-b species of varying lengths 
(Haass & Selkoe, 2007; Olsson et al., 2014; Takami et al., 2009). Amyloid-b can be 
released into the extracellular space or associate with lipid rafts to become internalized 
(Chen et al., 2017).  
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Figure 1.1. Amyloid precursor protein processing. Amyloid precursor protein (APP) 
can be processed through the non-amyloidogenic or amyloidogenic cleavage pathways. 
Through the non-amyloidogenic pathway, APP is first cleaved by a-secretase at a 
cleavage site within the amyloid-b sequence. The N-terminus is then released into the 
extracellular environment. The remaining C-terminus embedded in the membrane is then 
cleaved by g-secretase, releasing P3 and AICD into the extracellular and intracellular 
environments, respectively. When APP is processed through the amyloidogenic pathway, 
it is first cleaved by b-secretase, releasing the N-terminus into the extracellular space. 
The remaining C-terminal fragment (CTFb) is sequentially cleaved by g-secretase. AICD 
and Ab peptides are then released. Ab peptides of a certain length have a propensity to 
aggregate and can become pathological in nature. 
  
 
 
4 
 
Despite the known pathological effects of amyloid-b, APP and Ab also have 
physiological roles. The production of amyloid-b is naturally occurring, however when 
the net levels of amyloid-b become extreme, it becomes pathological in nature (Pearson 
& Peers, 2006). Amyloid-b is produced during normal metabolism in cultured primary 
cells and cell lines (Haass et al., 2003). APP and its cleaved protein fragments have been 
posited to play important roles in processes such as neuronal survival and synaptic 
activity. For example, synaptic activity has been shown to increase the production of 
amyloid-b, which creates a negative feedback loop and inhibits further synaptic activity 
(Lesne et al., 2005). The proposed explanation for the beneficial effects of synaptic 
inhibition is by controlling excessive glutamate release and protecting against 
excitotoxicity (Lesne et al., 2005). Additionally, in cortical neurons, the N-terminus 
released extracellularly following APP cleavage by a-secretase has been shown to 
promote cell survival and neurite extensions (Araki et al., 1991). Despite these pro-
survival roles of APP and amyloid-b, aberrant production and excessive protein levels are 
present in AD and are detrimental to cells.  
There are many mutations in the APP gene, located on chromosome 21, that result in 
preferential processing of APP through the amyloidogenic pathway (Haass et al., 1995; 
Rozpedek, Markiewicz, Diehl, Pytel, & Majsterek, 2015). These mutations occur around 
the b- and g-secretase cleavage sites and can lead to familial Alzheimer’s disease (FAD; 
Haass et al., 1995). Mutations near the b-secretase cleavage site lead to increased 
processing of APP through the amyloidogenic pathway, and mutations near the g-
secretase cleavage site lead to the generation of longer amyloid-b species (Haass et al., 
1995; Scheuner et al., 1996). These longer species of amyloid-b, such as Ab42, are more 
prone to aggregation than shorter fragments, such as Ab40 (Bentahir et al., 2006; 
Wakabayashi & De Strooper, 2008).   
In addition to mutations in the APP gene, there are mutations within the g-secretase 
enzyme that can alter APP processing. g-secretase is a multi-subunit enzyme composed of 
presenilin (PS1 or PS2), nicastrin, anterior pharynx-defective 1 (APH1), and presenilin 
enhancer 2 (PEN2; De Strooper, 2003; Haass & Selkoe, 1993; Iwatsubo, 2004; Kimberly 
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et al., 2003). Presenilin is believed to form the active site of this protein complex, and 
nicastrin helps to dock the protein substrate (Kimberly et al., 2003; Wakabayashi & De 
Strooper, 2008). There are over 200 identified mutations in both PS1 and PS2 combined 
that can alter its enzymatic activity (http://www.molgen.ua.ac.be/ADMutations/). g-
secretase has the ability to cleave the CFTb fragment at many sites, which generates 
amyloid-b peptides of varying lengths (Olsson et al., 2014). Mutations in the presenilin 
genes have been shown to increase CFTb cleavage into longer Ab fragments (Scheuner 
et al., 1996).  
Amyloid-b can aggregate into a fibrillar or an oligomeric form (Deshpande, Mina, Glabe, 
& Busciglio, 2006; Gouras, Olsson, & Hansson, 2015). Amyloid plaques are composed 
mainly of insoluble fibrillar amyloid-b peptides; however, it is thought that soluble 
oligomeric amyloid-b is more toxic to neurons than the fibrillar form (Deshpande et al., 
2006). It has been shown that soluble Ab42 aggregates into oligomers more readily than 
Ab40, due to the residues present at its C-terminus (Bitan et al., 2002; Murphy & Levine, 
2010). The total Ab42 burden present, as well as the ratio of Ab42/Ab40, factor into the age 
of disease onset (Chen et al., 2017; Duering, Grimm, Grimm, Schröder, & Hartmann, 
2005). Soluble amyloid-b aggregates have a heterogenous size distribution (Bitan et al., 
2002; Haass & Selkoe, 2007). Oligomers can be on the order of small molecular weights, 
such as dimers, trimers, and tetramers, and up to midrange molecular weights, such as 
hexamers and nonamers (Bitan et al., 2002; Chen et al., 2017).  
The clearance of amyloid-b is an important process that can be altered in Alzheimer’s 
disease. Several processes are naturally in place to counterbalance the production of Ab 
(Caccamo, Oddo, Sugarman, Akbari, & LaFerla, 2005; Iwata et al., 2000; Miners et al., 
2006; Yasojima, Akiyama, McGeer, & McGeer, 2001). Processes such as extracellular 
proteolytic degradation, endocytosis followed by intracellular proteolytic degradation, 
and transport out of the brain, are examples of potential mechanisms that are used (Chen 
et al., 2017; Iwata et al., 2000). Neprilysin (NEP) is a type 2 membrane glycoprotein that 
is the most efficient peptidase of amyloid-b (Iwata et al., 2000). It can be localized to 
cellular compartments such as the Golgi and endoplasmic reticulum (ER), and its active 
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site is located in the intraluminal and extracellular spaces (Chen et al., 2017). 
Interestingly, levels of neprilysin have been shown to be reduced in an age-dependent 
manner. In the hippocampi of AD patients, as well as in mouse models of Alzheimer’s 
disease, levels of neprilysin are significantly attenuated compared to controls (Caccamo 
et al., 2005; Miners et al., 2006; Yasojima et al., 2001). The relationship between 
amyloid-b production and clearance is an important balance to maintain, because 
perturbations in this system can lead to or accelerate the progression of Alzheimer’s 
disease.  
1.2 The Integrated Stress Response  
The Integrated Stress Response (ISR) is a conserved, adaptive pathway that allows cells 
to respond to and mitigate various environmental stresses (Pakos‐Zebrucka et al., 2016; 
Ron, 2002). These stress stimuli can be both intrinsic, such as endoplasmic reticulum 
stress, or extrinsic, for example amino acid or glucose deprivation (Harding et al., 2003; 
Pakos‐Zebrucka et al., 2016; Ron, 2002). The ISR begins with four protein kinases that 
each detect a specific type of stressor. These kinases are heme-regulated eukaryotic 
initiation factor-2a kinase (HRI), double stranded RNA-dependent protein kinase (PKR), 
PKR-like endoplasmic reticulum kinase (PERK), and general control non-derepressible 2 
(GCN2; Chen et al., 2011; Onuki et al., 2004; Pakos‐Zebrucka et al., 2016; Szegezdi, 
Logue, Gorman, & Samali, 2006; Ye et al., 2010). Excluding HRI, the ISR kinases are 
highly expressed in the mammalian brain (Ohno, 2014). The ISR kinases have conserved 
catalytic kinase domains and distinct regulatory domains, which allows for the detection 
of numerous stressors (J. J. Chen et al., 1991; Donnelly, Gorman, Gupta, & Samali, 
2013). PERK is a transmembrane protein that lies on the endoplasmic reticulum 
membrane and detects ER stress. Increased levels of unfolded or misfolded proteins and 
disruptions in calcium homeostasis are some of the stimuli that can induce ER stress 
(Carrara, Prischi, Nowak, Kopp, & Ali, 2015; Moore, Omikorede, Gomez, Willars, & 
Herbert, 2011; Pakos‐Zebrucka et al., 2016). PKR was initially discovered to become 
activated by viral infection, and subsequent research has determined that PKR also 
responds to more general stress signals, such as ER and oxidative stress (Onuki et al., 
2004). GCN2 mainly senses the availability of amino acids and becomes activated during 
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amino acid deprivation (Deval et al., 2009). Once a stressor has been detected, the 
corresponding kinase will dimerize and autophosphorylate, thus becoming active. The 
kinases converge by phosphorylating the a-subunit of eukaryotic initiation factor-2 
(eIF2a) at serine 51 (Figure 1.2; Baird & Wek, 2012; Ron, 2002). 
eIF2 is a heterotrimeric protein and it is composed of an a, b, and g subunit. It aids in the 
initiation of cap-dependent protein translation (Kimball, 1997). The a subunit of eIF2 
contains the regulatory phosphorylation site. Under non-phosphorylated conditions, eIF2 
binds with GTP and initiator methionine tRNA (Met-tRNAi) to form the ternary complex 
(TC). The ternary complex then binds to the 40S ribosomal subunit, along with a few 
more initiation factors, to form the 43S pre-initiation complex (PIC; Hinnebusch & 
Lorsch, 2012). The 43S PIC is recruited to the 5’ cap of the mRNA transcript and begins 
scanning for the AUG start codon. Once the Met-tRNAi binds to the AUG start codon, 
eIF2-GTP is hydrolyzed to eIF2-GDP with the help of eIF5 (Das, Maiti, Das, & Maitra, 
1997). eIF2-GDP disassociates from the 40S ribosomal complex and allows for the 60S 
ribosomal subunit to be recruited and begin translation elongation. GDP-bound eIF2 is 
inactive and needs to be recycled back into eIF2-GTP in order to be able to facilitate a 
new round of translation initiation (Krishnamoorthy, Pavitt, Zhang, Dever, & 
Hinnebusch, 2001). This recycling is aided by the guanine exchange factor (GEF) eIF2B 
(Gomez, Mohammad, & Pavitt, 2002). When eIF2 becomes phosphorylated on the a 
subunit, its affinity to bind eIF2B is enhanced. Phosphorylated eIF2a becomes a 
competitive inhibitor of the GEF. eIF2B concentrations in the cell are much lower than 
that of eIF2, therefore even slight increases in P-eIF2a can disrupt the GEF activity of 
eIF2B (Krishnamoorthy et al., 2001; Pavitt, Ramaiah, Kimball, & Hinnebusch, 1998). 
During stress conditions when eIF2a is phosphorylated, the recycling of GDP-eIF2 back 
to its active form is reduced. The initiation of the TC and 43S PIC are reduced, thereby 
attenuating the initiation of cap-dependent protein translation (Harding et al., 2000). 
Despite this halt in global protein translation, there is selective upregulation of the 
translation of select transcripts, including activating transcription factor 4 (ATF4; Baird 
& Wek, 2012; Lu, Harding, & Ron, 2004). ATF4 is strongly considered to be the effector 
of the ISR because it modulates the expression of stress-induced genes.  
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Figure 1.2. The Integrated Stress Response. The integrated stress response (ISR) is a 
conserved intracellular pathway that allows cells to respond to a variety of stressors. HRI, 
PKR, GCN2, and PERK are the four kinases of the ISR and they each detect specific 
stressors in the cellular environment. Once a stress stimulus is detected, the 
corresponding kinase dimerizes and auto-phosphorylates, thereby becoming activated. 
The kinases converge upon and phosphorylate eIF2a, resulting in two main 
consequences: a reduction in global protein translation and a selective increase in 
translation of a subset of mRNA transcripts. ATF4 protein levels are elevated in response 
to cellular stress and the transcription factor is able to translocate into the nucleus. Once 
in the nucleus, ATF4 modulates the expression of downstream target genes involved in 
processes such as amino acid synthesis, autophagy, and apoptosis.  
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1.2.1 Activating Transcription Factor 4 
ATF4 is a member of the activating transcription factor/cyclic AMP response element 
binding protein (ATF/CREB) family (Karpinski, Morle, Huggenvik, Uhler, & Leiden, 
1992; Wortel, van der Meer, Kilberg, & van Leeuwen, 2017). Also known as cAMP-
response element binding protein 2 (CREB-2), ATF4 contains a basic leucine zipper 
(bZIP) domain and is able to homo- or heterodimerize with other bZIP transcription 
factors (Ameri & Harris, 2008; Karpinski et al., 1992). The three main subfamilies that 
ATF4 dimerizes with are: ATF/CREB, FOS/JUN, and CCAAT enhancer binding protein 
(C/EBP) (Vallejo, Ron, Miller, & Habener, 1993; Wortel et al., 2017). The partners that 
ATF4 interacts with are critical in determining its transcriptional selectivity (Hai & 
Curran, 1991). ATF4 homodimers are unstable even when bound to DNA, while 
heterodimers are more stable and bind more readily to DNA targets (Hai, Liu, Coukos, & 
Green, 1989; Podust, Krezel, & Kim, 2001; Wortel et al., 2017). ATF4 binds to DNA 
through its basic region upstream of the bZIP domain, which is composed of many 
positively charged amino acids (Ameri & Harris, 2008; Karpinski et al., 1992). ATF4 
heterodimers can bind to various target genes through cAMP responsive elements (CREs) 
and C/EBP-ATF response elements (CAREs) in the DNA sequence (Baird & Wek, 2012; 
Hai & Curran, 1991; Vallejo et al., 1993; Wortel et al., 2017). The various transcription 
factors that ATF4 heterodimerizes with determine the outcome of ISR signaling.  
ATF4 protein expression is strictly regulated. It has many functional domains that allow 
the interaction with and modulation by various factors (Figure 1.3; Dey et al., 2010; 
Wortel et al., 2017). The N-terminal domain of the protein contains an interaction site for 
the histone acetyltransferase p300. This interaction stabilizes ATF4 protein by blocking 
ubiquitination and subsequent proteasomal degradation, however this occurs 
independently from the acetyltransferase activity of p300 (Ameri & Harris, 2008; Lassot 
et al., 2005). The half-life of ATF4 protein is approximately 2-4 hours, therefore protein 
stabilization is important for prolonging its activity (Baird & Wek, 2012; Rutkowski et 
al., 2006). The oxygen-dependent degradation domain (ODDD) of ATF4 offers another 
avenue of protein stabilization by interacting with prolyl hydroxylase domain 3 (PHD3), 
a hypoxia-inducible protein (Köditz et al., 2007; Wortel et al., 2017). Downstream of the 
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p300 and ODDD interaction domains lies a motif recognized by b-transducin repeats 
containing protein (b-TrCP). b-TrCP is associated with an E3-ubiquitin ligase (Lassot et 
al., 2001; Wortel et al., 2017). b-TrCP recognizes nuclear ATF4 phosphorylated on 
specific sites within the b-TrCP recognition domain and leads to ubiquitination and 
proteasomal degradation of ATF4 (Lassot et al., 2001). In addition to protein interactions 
that modulate ATF4 stability, ATF4 is also subject to many post-translational 
modifications, including phosphorylation, methylation, ubiquitination, and acetylation 
(Wortel et al., 2017).  
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Figure 1.3. Functional domains of the ATF4 protein. Activating transcription factor 4 
(ATF4) is known as the effector of the integrated stress response. ATF4 contains many 
functional domains, including a leucine zipper that allows it to heterodimerize with other 
bZIP transcription factors. ATF4 binds to DNA through its basic region, which lies 
upstream of the leucine zipper. ATF4 protein stability is modulated in part by b-TrCP, 
which is a ubiquitin-associated protein that targets ATF4 for proteasomal degradation. 
The oxygen-dependent degradation domain (ODDD) is an additional region that 
modulates ATF4 stability. During hypoxic conditions, PHD3 interacts with ATF4 
through the ODDD domain and promotes protein stability. At the N-terminus, there is an 
interaction site for the histone deacetylase p300. This interaction stabilizes ATF4 
blocking ATF4 ubiquitination and subsequent proteasomal clearance.  
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The translation of ATF4 is paradoxically enhanced under levels of low global protein 
translation, when eIF2a is phosphorylated and the availability of eIF2-GTP-Met-tRNAi 
ternary complexes are low (Harding et al., 2000; Pakos‐Zebrucka et al., 2016; Wek, 
Jiang, & Anthony, 2006). There is still debate within the field, however the primary 
hypothesis by which phosphorylated eIF2a preferentially translates ATF4 is through 
delayed translation reinitiation and upstream open reading frames (uORFs; Ameri & 
Harris, 2008; Baird & Wek, 2012; Fernandez, Yaman, Sarnow, Snider, & Hatzoglou, 
2002; Harding et al., 2000). uORFs lie 5’ to the coding sequence of transcripts. 
Translation initiation of ATF4 occurs when the 43S PIC binds to the 5’ cap of the 
transcript and scans until it reaches uORF1. uORF1 is translated and eIF2-GDP 
disassociates from the mRNA, however the 40S ribosomal subunit continues scanning the 
transcript. When eIF2-GTP levels are high, under non-stressed conditions, the ternary 
complex is readily acquired by the small ribosomal subunit and translation is reinitiated 
at the next start codon on the transcript. This subsequent initiation codon is within 
uORF2 of the ATF4 mRNA and is inhibitory (Baird & Wek, 2012; Vattem & Wek, 
2004). uORF2 overlaps out-of-frame with the coding region of the ATF4 transcript and 
causes dissociation of the ribosomal complex (Lu et al., 2004; Young & Wek, 2016). 
When cells are under stressed conditions, eIF2 TC levels are scarce and the 40S 
ribosomal subunit is unable to acquire a TC in time to reinitiate translation at uORF2. 
Consequently, the ribosomal subunit bypasses the inhibitory uORF and is able to acquire 
a ternary complex in sufficient time to recognize the coding region of the ATF4 transcript 
(Pitale, Gorbatyuk, & Gorbatyuk, 2017; Vattem & Wek, 2004). Preferential translation of 
ATF4 during periods of cellular stress results in greater protein expression (Baird & Wek, 
2012; Dey et al., 2010).  
ATF4 is expressed throughout all cell types and plays an important role in embryonic 
development (Ameri & Harris, 2008). Studies using murine whole-embryo ATF4 
knockouts have revealed that ATF4 plays a critical role in lens formation in the eye, 
skeletal development, hematopoiesis, lipid metabolism, and fertility, among others 
(Fischer et al., 2004; Hettmann, Barton, & Leiden, 2000; Masuoka & Townes, 2002; 
Tanaka et al., 1998; Wang et al., 2010; Yang et al., 2004). Therefore, ATF4 knockout 
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mice display microphthalmia, stunted growth and low bone mass, and infertility. These 
developmental abnormalities highlight the importance of ATF4 in normal cell 
functioning under non-stressed conditions.  
When cells are experiencing stress, ATF4, the effector of the integrated stress response, 
interacts with other transcription factors and modifies the expression of stress-induced 
genes. These target genes are involved in processes such as amino acid synthesis, 
autophagy, and protein folding (B’Chir et al., 2013; Harding et al., 2003). The reduction 
in global protein translation that occurs due to phosphorylation of eIF2a reduces the 
energy demands of the cell. This allows the cell to prioritize alleviating the stress it is 
experiencing. For instance, in response to ER stress, global protein translation is 
attenuated, thus reducing the load of naïve proteins entering the ER. Consequently, the 
cell can increase the clearance of unfolded proteins in the ER or increase the expression 
of ER chaperones (Joshi et al., 2016; Luo, Baumeister, Yang, Abcouwer, & Lee, 2003). 
The process of autophagy is an important protective pathway that cells utilize to degrade 
proteins, recycle amino acids, and maintain energy levels. It has been shown that eIF2a 
and ATF4 are necessary for the expression of many autophagic genes and ATF4 binds to 
amino acid response elements (AAREs) in the promoter regions of these genes (B’Chir et 
al., 2013). In addition, ATF4 binds to and activates the promoter of 78 kDa glucose-
related protein, also called binding immunoglobin protein, (Grp78/BiP), an ER chaperone 
(Lee, 2001; Luo et al., 2003). This increases the protein folding capacity of the ER. Once 
cells have adequately dealt with a stressor and returned to homeostasis, they must 
deactivate the integrated stress response. Dephosphorylation of eIF2a allows regular 
protein translation to proceed and is mediated by the protein phosphatase 1 (PP1) 
complex. It is composed of a catalytic subunit and a regulatory subunit. Growth arrest 
and DNA damage-inducible protein 34 (Gadd34) is one of the regulatory subunits that 
can bind with the PP1 catalytic subunit (Ma & Hendershot, 2003). ATF4 induces the 
expression of Gadd34, which creates a negative feedback loop to deactivate the ISR and 
restore global protein translation (Novoa et al., 2003; Pakos‐Zebrucka et al., 2016).  
It is generally accepted that transient activation of the ISR and ATF4 upregulation favour 
cell survival. In contrast, chronic stress that results in sustained ISR activity and ATF4 
14 
 
protein levels can lead to apoptosis and aberrant cell death (Pitale et al., 2017; Rutkowski 
et al., 2006; Wortel et al., 2017). One of the most well-characterized ATF4 target genes is 
C/EBP homologous protein (CHOP), also known as Gadd153. CHOP is a known pro-
apoptotic protein and it is also a bZIP transcription factor that can heterodimerize with 
ATF4 (Fawcett, Martindale, Guyton, Hai, & Holbrook, 1999; Han et al., 2013; Pitale et 
al., 2017). In response to ER stress, it has been demonstrated that ATF4-CHOP binds to 
the tribbles-related protein 3 (Trib3) promoter and increases expression, eventually 
leading to apoptosis (Ohoka, Yoshii, Hattori, Onozaki, & Hayashi, 2005). Additionally, a 
growing body of evidence suggests that CHOP can also lead to apoptosis through the 
modulation of the B-cell lymphoma-2 (BCL-2) protein family (Galehdar et al., 2010; 
Szegezdi et al., 2006; Youle & Strasser, 2008).  
The switch from pro-survival to pro-death ISR outcomes is highly context-dependent, 
and factors such as cell type and the nature or duration of the stress can influence the 
result (Baird & Wek, 2012; Rutkowski et al., 2006; Wortel et al., 2017). For example, in 
mouse embryonic fibroblasts (MEFs), the induction of ER stress causes activation of the 
PERK arm of the ISR and a subsequent increase in ATF4 protein levels (Harding et al., 
2003). The researchers found that ATF4-deficient MEFs are more sensitive to oxidative 
stress and endogenous ATF4 upregulation in wildtype cells helps promote survival. 
Additionally, high levels of ATF4 protein have been found in hypoxic regions of primary 
human malignant tumours from breast, skin, and cervical tissues (Bi et al., 2005). Despite 
pro-survival evidence in some tissues, ATF4 has been shown to favour pro-death 
outcomes in neurons (Galehdar et al., 2010; Lange et al., 2008). Research suggests that 
ATF4-deficient neurons are resistant to oxidative and ER stress and subsequent 
apoptosis.  
1.2.2 ISR and Apoptosis 
The Bcl-2 protein was first discovered in B-cell follicular lymphomas as a pro-survival 
protein that inhibits cell death when overexpressed (Tsujimoto, Cossman, Jaffe, & Croce, 
1985; Vaux, Cory, & Adams, 1988). Bcl-2 is a member of the BCL-2 protein family, 
which has at least 12 core proteins, as well as numerous proteins that share homology 
through the BH3 motif (Zha, Aimé-Sempé, Sato, & Reed, 1996). The BCL-2 family 
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consists of pro-survival, pro-apoptotic, and BH3-only members that interact to determine 
cell fate. Pro-survival members inhibit cell death by binding to pro-apoptotic members 
and preventing them from exerting their effects (Willis et al., 2007; Youle & Strasser, 
2008). BH3-only proteins promote apoptosis by binding to and sequestering pro-survival 
members, thus freeing pro-apoptotic proteins (Willis et al., 2007). Apoptosis that occurs 
through the activation of pro-death BCL-2 members is also referred to as the intrinsic 
mitochondrial pathway due to the role that mitochondria have in initiating apoptosis. Bcl-
2-associated X protein (BAX) and Bcl-2 homologous antagonist killer (BAK) are pro-
apoptotic BCL-2 proteins that induce the permeabilization of the outer mitochondrial 
membrane (OMM) when derepressed (Kuwana et al., 2002). When the OMM is 
permeabilized, apoptogenic molecules are released into the cytoplasm and cause 
activation of apoptotic protease-activating factor-1 (APAF1). APAF1 in turn induces 
activation of caspase-9 and caspase-3, culminating in apoptosis (Li et al., 1997). P53-
upregulated modulator of apoptosis (PUMA) is a well-known BH3-only member that is 
induced in response to p53-dependent and -independent mechanisms and is able to bind 
to and inhibit all BCL-2 pro-survival members (Cregan et al., 2004; Galehdar et al., 2010; 
Steckley et al., 2007). Our lab has previously shown that PUMA is upregulated in 
response to oxidative and ER stressors, and PUMA-deficient neurons are protected 
against oxidative and ER stress-induced apoptosis (Galehdar et al., 2010; Steckley et al., 
2007). In addition, our lab has shown that ATF4-deficient neurons have less PUMA 
induction and attenuated cell death in response to these stressors (Galehdar et al., 2010). 
Further studies have determined that CHOP-deficient neurons also have attenuated 
PUMA expression and apoptosis, and that CHOP-mediated induction of PUMA might 
occur through the AKT-FOXO3a pathway (Ghosh, Klocke, Ballestas, & Roth, 2012).  
1.3 The ISR in Alzheimer’s disease 
1.3.1 Cellular stress in AD 
The integrated stress response has been implicated in Alzheimer’s disease. Specifically, 
high levels of ISR markers have been found in mouse models of Alzheimer’s disease, as 
well as in humans with AD. Amyloid-b can induce high levels of neuronal stress, and the 
ISR is a way that neurons can try to mitigate cellular stress. In post mortem analyses from 
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AD patients, more ATF4-positive axons were found in the hippocampus and other 
subcortical structures compared to age-matched controls, and these axons were found 
surrounding amyloid plaques (Baleriola et al., 2014). Higher levels of phosphorylated 
eIF2a have also been found in AD patients’ brains compared to healthy controls (Chang, 
Wong, Ng, & Hugon, 2002; Ma et al., 2013). Additionally, elevations in phosphorylated 
eIF2a and ATF4 levels have been measured in APP/PS1 and 5XFAD mouse models of 
AD (Ma et al., 2013). Cellular stress activates ISR kinases, increases phosphorylated 
levels of eIF2a, reduces global protein translation, and facilitates translation of select 
transcripts. Examples of transcripts that are preferentially translated include ATF4 and 
BACE1. BACE1, or b-secretase, cleaves amyloid precursor protein through the 
amyloidogenic pathway, which results in the production of Ab species of varying lengths. 
BACE1 is considered to be the rate-limiting enzyme in the production of pathogenic 
amyloid-b (Vassar, Kovacs, Yan, & Wong, 2009). Under basal conditions, the translation 
of BACE1 is suppressed (Lammich, Schöbel, Zimmer, Lichtenthaler, & Haass, 2004). 
ATF4 and BACE1 both contain upstream open reading frames in their 5’ untranslated 
regions, which provides one explanation of preferential translation during periods of 
cellular stress (De Pietri Tonelli et al., 2004; Guix, Sartório, & ILL-Raga, 2019). 
Elevated levels of phosphorylated eIF2a and BACE1 expression have been found in the 
5XFAD mouse model of Alzheimer’s disease (Devi & Ohno, 2014). PERK 
haploinsufficiency in these mice attenuated high levels of phosphorylated eIF2a and led 
to a reduction in BACE1 expression. Additionally, the expression of the Ab-degrading 
enzyme neprilysin was reduced. PERK haploinsufficiency in these animals also led to the 
restoration of NEP expression (Devi & Ohno, 2014). Therefore, PERK dysregulation in 
the 5XFAD mouse model leads to increased amyloid-b production as well as decreased 
amyloid-b clearance. High levels of BACE1 protein and activity levels have also been 
found in the neocortex in Alzheimer’s disease patients (Fukumoto, Cheung, Hyman, & 
Irizarry, 2002; O’Connor et al., 2008).  
Evidence also suggests a link between downstream ATF4 and g-secretase expression 
(Mitsuda, Hayakawa, Itoh, Ohta, & Nakagawa, 2007; Ohta et al., 2011). g-secretase 
cleaves APP once it has first been cleaved by either a-secretase or BACE1, generating 
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amyloid-b species of varying lengths. Presenilin-1, which forms the active site of the g-
secretase complex, contains an amino acid response element in its gene promoter. It has 
been demonstrated that amino acid deprivation activates the ISR kinase GCN2 and leads 
to phosphorylation of eIF2a and increased expression of ATF4. Interestingly, it has been 
found that ATF4 binds to the AARE sequence in the PS1 gene and increases the 
expression of g-secretase cofactors in response to amino acid deprivation (Mitsuda et al., 
2007). g-secretase activity is increased in response to ER stress through the expression of 
ATF4 (Ohta et al., 2011).  
In addition to the link between ATF4 and Ab production, ATF4 has also been shown to 
induce neurodegeneration in response to amyloid-b treatment (Baleriola et al., 2014). 
Axonally applied Ab42 induced local translation of Atf4 mRNA, retrograde transport to 
the soma, and increased expression of ATF4-responsive genes such as CHOP. Prolonged 
CHOP expression led to apoptosis in these neurons, which was reversed when axonal 
translation of ATF4 was inhibited (Baleriola et al., 2014). Thus, abundant evidence 
suggests that ATF4 upregulation seen in Alzheimer’s disease may act as both an 
upstream initiator for pathological amyloid-b production and also act downstream of 
amyloid-b as an effector of this stress leading toward neurodegeneration (Wei, Zhu, & 
Liu, 2015).  
1.3.2 ISR and Memory 
On a cellular level, Alzheimer’s disease can be additionally characterized by synaptic 
dysfunction (Masliah et al., 1994; Nelson et al., 2009). Long-term potentiation (LTP), 
first characterized in the 1970s in the hippocampus, is a phenomenon that allows for the 
study of synaptic plasticity (Bliss & Lomo, 1973). The main principle behind LTP is that 
synaptic connections that are frequently stimulated will be strengthened to facilitate 
neuronal communication (Bliss & Collingridge, 1993). In experimental settings, LTP is 
typically induced by applying a short, high-frequency burst of stimulation, called a 
tetanus, to synapses in a slice of neuronal tissue, most commonly the hippocampus (Bliss 
& Collingridge, 1993). The tetanic stimulation can induce enhanced synaptic responses 
as measured by field recordings of excitatory postsynaptic potentials.  
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Multiple researchers have found that elevations in ISR members are detrimental to long-
term potentiation. Costa-Mattioli et al. demonstrated that the genetic removal of GCN2 
resulted in a more robust expression of LTP compared to wildtype hippocampal slices. 
This GCN2 deletion also led to decreased hippocampal ATF4 mRNA translation (Costa-
Mattioli et al., 2005). Furthermore, in APP/PS1 mice, PERK removal rescued the spatial 
memory and synaptic plasticity deficits seen in APP/PS1 mice (Ma et al., 2013). In 
addition to AD mouse models that contain mutations in APP and PS1 genes, mice 
expressing the human form of the apolipoprotein E (ApoE) e4 allele have also been 
utilized as models of sporadic Alzheimer’s disease (SAD; Segev et al., 2015). ApoE 
plays a role in lipid metabolism and can promote the clearance of amyloid-b in the brain. 
There are three polymorphic ApoE alleles and having at least one e4 allele is associated 
with a higher risk of developing AD (Strittmatter & Roses, 1997). ApoE e4 can induce 
ER and oxidative stress, leading to high levels of phosphorylated eIF2a (Segev et al., 
2015; Segev, Michaelson, & Rosenblum, 2013). Inhibition of PKR in ApoE e4 mice 
rescued impairments in fear conditioning and reduced hippocampal ATF4 expression to 
control levels (Segev et al., 2015).  
Phosphorylated eIF2a has been implicated in LTP as well. It has been demonstrated that 
by blocking the dephosphorylation of eIF2a, thus increasing the levels of phosphorylated 
eIF2a, the initiation of LTP is impeded (Costa-Mattioli et al., 2007). The conversion of 
early phase to late phase LTP is unable to occur when phosphorylated eIF2a levels are 
increased. It has been well-documented that de novo protein synthesis is necessary for 
sustaining LTP (T. Ma et al., 2013). Following tetanic induction of LTP, levels of 
phosphorylated eIF2a are physiologically reduced (Trinh et al., 2014). It has been shown 
that ATF4 can interact with and inhibit CREB, thereby inhibiting the conversion from 
early to late phase LTP. By inhibiting ATF4, the threshold needed to induce long-term 
potentiation in mice was lowered and hippocampal-based spatial memory was increased 
(Chen et al., 2003).  
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1.4 Rationale  
ATF4 is part of the stress-responsive ISR pathway and becomes upregulated in response 
to various cellular stressors. Stimuli such as oxidative and endoplasmic reticulum 
stressors have been shown to reliably induce the ISR and ATF4 induction. Within the 
context of Alzheimer’s disease, high levels of neuronal stress have been measured. The 
ISR has been implicated in AD as a mechanism that can exacerbate the effects of 
amyloid-b and also be upstream initiators of synaptic dysfunction and pathological 
hallmarks (Wei et al., 2015). Previous research has demonstrated that the ISR and ATF4 
are induced in animal models of Alzheimer’s disease, as well as in the brains of AD 
patients (Baleriola et al., 2014; Chang et al., 2002; Ma et al., 2013). The knockdown of 
an ER stress-inducible neurotrophic factor was shown to exacerbate amyloid-b toxicity, 
while overexpression lowered the levels of ER stress and ATF4, partially protecting 
against neuronal death (Xu et al., 2019). Prolonged ATF4 activation has been shown to 
induce the expression of pro-apoptotic genes and promote neuronal death. Previous work 
in our lab has demonstrated that oxidative and ER stress lead to apoptosis in a PUMA-
dependent manner (Galehdar et al., 2010). However, it remains unclear whether ATF4-
mediated death in response to amyloid-b occurs in a PUMA-dependent manner.  
1.5 Hypothesis  
Amyloid-b-induced neuronal death occurs through ATF4-mediated upregulation of the 
pro-apoptotic gene PUMA.  
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Chapter 2  
2 Materials and Methods 
2.1 Animals 
All animal procedures were performed in accordance with the guidelines set forth by the 
Animal Care Committee at Western University. Animals were housed in a 12h light-dark 
cycle and food and water were provided ad libitum. Mice with an ATF4-null mutation 
were obtained from Dr. Tim Townes and Dr. Joe Sun (University of Alabama at 
Birmingham, AL; Masuoka & Townes, 2002). Mice harboring PUMA-null mutations 
were generated in the lab of Dr. Andreas Strasser (Walter and Eliza Hall Institute of 
Medical Research, Bundoora, Victoria, Australia) and obtained from The Jackson 
Laboratory (C57BL/6-Bbc3tm1Ast/J, #011067). Both mouse strains were maintained on a 
C57BL/6 background. Heterozygous animals were bred to generate wildtype and 
knockout littermates for ATF4 and PUMA strains.  
2.1.1 Genotyping 
Mouse genomic DNA was isolated by adding DNA lysis buffer (100 mM Tris, 5mM 
EDTA, 0.2% weight per volume SDS, 200 mM NaCl) and Proteinase K (Bioshop, 
#PRK222) to embryonic tail clip samples. Samples were incubated overnight in a 55ºC 
heat block. Phenol:Chloroform:Isoamyl alcohol (Fisher Scientific, #BP1752I-400) was 
added to the samples and tubes were inverted for approximately 1 minute. Tubes were 
spun for 10 minutes at 12,000 rpm at room temperature. The top aqueous layer was 
transferred to a clean tube, isopropanol was added, and the tubes were inverted for 
approximately 30 seconds. Tubes were spun for 10 minutes at 10,000 rpm at 4ºC and the 
supernatant was aspirated. The DNA pellet was washed with 70% ethanol and spun again 
for 5 minutes at 10,000 rpm at 4ºC. The supernatant was discarded, and the pellet was 
dried at room temperature. The pellet was then dissolved in TE buffer (ThermoFisher, 
#AM9849) and incubated at 37ºC for one hour.  
The ATF4 primer sequences used for genotyping are provided in Appendix A. The PCR 
reaction contained dNTPs, reaction buffer, MgCl2, Q solution, Taq polymerase, ddH2O, 5 
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µM of each of the three primers, and 2 µL of DNA. All PCR reagents were purchased 
from Qiagen (#201207) except for dNTPs, which were purchased from Life Technologies 
(#10297018). The PCR cycling conditions were as follows: initial activation at 95ºC for 2 
minutes; denaturation at 94ºC for 20 seconds; annealing at 62ºC for 30 seconds; 
elongation at 68ºC for 1.5 minutes; final extension at 68ºC for 10 minutes; and held at 
4ºC. The denaturation, annealing, and elongation steps were repeated for 30 cycles prior 
to the final extension.  
PUMA embryos were genotyped using the primer sequences provided in Appendix B. 
The PCR reaction mix was the same as that used for ATF4 genotyping. The cycling 
conditions were: initial activation at 94ºC for 2 minutes; denaturation at 94ºC for 20 
seconds; annealing at 60ºC for 30 seconds; elongation at 72ºC for one minute; final 
extension at 72ºC for 4 minutes; and held at 4ºC. The denaturation, annealing, and 
elongation steps were repeated for 32 cycles prior to the final extension.  
2.2 Cell culture  
2.2.1 Primary cortical neurons  
Primary cortical neurons were harvested from mice on embryonic day 14.5-15.5 (E14.5-
15.5). Pregnant females were injected intraperitoneally with 400 µL euthanyl, at a 
concentration of 54 mg/mL diluted in 0.9% saline, followed by cervical dislocation. The 
embryos were removed from the uterus and placed into a petri dish filled with 1 x Hank’s 
Balanced Salt Solution (HBSS; GibcoÒ, #14170-112) stored on ice. The brains were 
removed from the embryos, the cortices were isolated, and the meninges were removed. 
The cortices from each embryo were processed separately. Tail clip samples were also 
collected from each embryo for genotyping purposes.  
Cortices were dissected in calcium- and magnesium-free 1x HBSS and stored in 1x 
HBSS on ice until ready to process. To dissociate the primary neurons, cortices from 
individual pups were incubated in 500 µL 1x HBSS supplemented with 1x trypsin 
(Sigma, #T4549) and 1.2 mM MgSO4 at 37˚C for 25 minutes in a tube rotator. The 
trypsin solution was inhibited by adding 600 µL of 1x HBSS supplemented with 1.2 mM 
MgSO4, 0.25 mg/mL DNAse I (Worthington, #LS002139), and 0.2 mg/mL trypsin 
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inhibitor (Roche, #10109878001). The samples were thoroughly mixed and centrifuged at 
400 x g for 5 minutes. The supernatant was aspirated, and the tissue pellet was 
resuspended in 1 mL of 1x HBSS supplemented with 3 mM MgSO4, 0.8 mg/mL DNAse 
I, and 1.25 mg/mL trypsin inhibitor. The tissue was then mechanically dissociated by 
triturating the pellet 10-15 times using a flame-polished pipette. The cell suspension was 
centrifuged at 400 x g for 5 minutes. The supernatant was removed, and the cell pellet 
was resuspended in 2 mL of cortical neuron medium, composed of Neurobasal Plus 
medium (NBM; ThermoFisher, #A35829-01) supplemented with 1x B27 plus 
(ThermoFisher, #A35828-01), 0.5x Glutamax (ThermoFisher, #35050-061), and 50 
U/mL penicillin: 50 μg/mL streptomycin (PenStrep; ThermoFisher, #15140-122).  
The cell suspensions were then diluted in cortical neuron media to a density of 6x105 
cells/mL and plated in 35 mm (2 mL; 1.2x106 cells/dish) or 4-well (500 µL; 3x105 
cells/well) dishes. The Nunclon∆ surface cell culture dishes (ThermoScientific, #150318, 
#176740) were coated overnight prior to use with poly-L-ornithine (Sigma, #P4957) 
diluted 1:10 in ddH2O (Invitrogen, #10977023) and incubated at room temperature. Prior 
to plating the cortical neurons, the dishes were rinsed using ddH2O and left to dry 
completely. Cultures were kept in an incubator at 37˚C and 5% CO2 until used for 
experiments. Cultured neurons were used following 5-7 days in vitro (5-7 DIV).  
2.2.2 Drugs 
The following protocol was used to resuspend amyloid-b1-42 lyophilized peptide 
(rPeptide, #A-1001-2) and amyloid-b1-42 scrambled lyophilized peptide (rPeptide, #A-
1004-2). The lyophilized peptides were equilibrated at room temperature 30 minutes prior 
to processing. Amyloid-b peptide was resuspended in 1 mL 1,1,1,3,3,3-Hexafluoro-2-
Propanol (HFIP; Aldrich, #105228-5G) at 1 mg/mL, vortexed, and quickly aliquoted 
equally into two tubes and sealed. The tubes were then incubated at room temperature for 
2 hours to allow for monomerization of the peptide. The vials were then opened and 
concentrated under vacuum using a SpeedVacÒ centrifuge (ThermoSavant, #ISS110). 
The amyloid-b peptide films were sealed and stored at -80˚C until further use. One 
amyloid-b film, 500 µg, was resuspended in 115 µL dimethylsulfoxide (DMSO; Sigma, 
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#D2650) to obtain a concentration of 1 mM Ab. Ab/DMSO was sonicated in a Branson 
3510 water bath for 10 minutes and then divided into 5 µL aliquots. Resuspended 
aliquots of amyloid-b were stored at -20˚C until needed.  
A single Ab1-42 peptide is approximately 4.5 kDa in size, therefore, dimers and higher 
order oligomers should be between 10 kDa and 25 kDa. To ensure the Ab peptide film 
had been properly resuspended, aliquots were used to check the size of the peptide. Each 
aliquot was incubated with 15 µL PBS overnight at 4˚C to allow for oligomerization. An 
equal volume of non-reducing loading dye was added, and the samples were run on a 
15% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) at fixed 90V. Once the 
samples had run down most of the gel, the gel was stained with ImperialÔ Protein Stain 
(ThermoScientific, #24615) for 1h at room temperature and rinsed overnight with milliQ 
water (Figure 2.1).  
Prior to treatments, 1 mM aliquots of Ab1-42 and Ab1-42 scrambled peptide were diluted in 
conditioned cortical neuron medium to achieve a final concentration of 1µM when added 
to the cultures. A concentration of 1 µM was used for all treatments with Ab1-42 and Ab1-
42 scrambled. This concentration was chosen based on a dose response experiment, where 
1 µM was the lowest concentration that reliably induced neuronal stress and ATF4 
expression. 
Thapsigargin (TG; Sigma, #T9033) is an endoplasmic-reticulum stressor and was used as 
a positive control to ensure the ISR was being induced. A 1 mM stock solution was made 
by solubilizing TG in DMSO. All treatments were diluted in conditioned cortical neuron 
medium and a final concentration of 1 µM was achieved when added to the neuronal 
cultures.  
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Figure 2.1. Oligomeric and scrambled amyloid-b peptides. Amyloid-b and scrambled 
amyloid-b peptide were resuspended and run on an SDS-PAGE gel. Gels were stained to 
visualize the size of the peptides.  
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2.3 Protein extraction and quantification  
Following appropriate treatment times, cells were rinsed with 1 x phosphate buffered 
saline (PBS) and then lysed directly in the cell culture dishes using RIPA buffer (Sigma, 
#R0278) supplemented with 1:100 phosphatase inhibitor cocktail (Sigma, #P5726) and 
1:100 protease inhibitor cocktail (Sigma, #P8340). Cells were scraped and transferred 
into 1.5 mL microcentrifuge tubes. Tubes were placed on ice for a minimum of 30 
minutes. Samples were centrifuged at 12,000 x g for 15 minutes at 4˚C. The supernatant 
was transferred to a fresh, labeled tube and samples were stored at -80˚C until further use.  
To determine the protein concentration of the samples, the PierceÔ BCA Protein Assay 
Kit (ThermoScientific, #23225) was performed according to the user guide. Using a 
SpectraMax M5 multi-mode microplate reader (Molecular Devices), absorbance of the 
samples was measured at 562 nm. The absorbance values of a standard curve were used 
to calculate the concentrations of protein samples.  
2.4 RNA isolation and quantification  
TRIzolÔ reagent (Invitrogen, #15596026) was used to isolated RNA from cultured 
neurons. The manufacturer’s protocol was followed. RNA concentrations of samples 
were measured using a NanoDrop1000 Spectrophotometer (ThermoScientific). Samples 
were diluted to 10 ng/µL in ddH2O stored at -80˚C until used.  
2.5 Western blot analysis 
Protein extracts were separated using 12% SDS-PAGE run at constant 30 mA. Protein 
gels were then transferred to Immun-BlotÒ PVDF membranes (BioRad, #1620177) and 
blocked in 5% milk diluted in 1 x TBST. Membranes were probed with primary 
antibodies, diluted 1:1000 in blocking solution, targeting ATF4 (Abcam, #184909) and 
cyclophilin b (Abcam, #178397) overnight at 4˚C. Cyclophilin b was used as a loading 
control. Membranes were then rinsed with 1 x TBST and probed with horseradish 
peroxidase secondary antibody conjugate (BioRad, #1706515) diluted 1:10,000 in 
blocking solution for 1h at room temperature. Clarity Western ECL Substrate (BioRad, 
#1705061) was used to visualize immunoreactive bands. Western blots were first 
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quantified by normalizing ATF4 levels to Cyclophilin b levels for each sample across 
experiments. A mean normalized ATF4 value was generated from control-treated 
samples. This mean value was used to re-normalize all treatments and generate a fold 
change in ATF4 protein levels relative to control.  
2.6 Real-time quantitative RT-PCR analysis 
Reverse transcription PCR analysis was performed using the Quantifast RT PCR Kit 
(Qiagen, #204154). Primer sequences targeting CHOP, Trib3, Gadd45a, 4eBP1, PUMA, 
and S12 are provided in Appendix C. The reaction setup and cycling protocol were 
administered according to manufacturer guidelines. Each real-time PCR reaction had a 
total volume of 25 µL which included 40 ng of RNA and forward and reverse primers at 
a concentration of 1 µM. A CFX ConnectÔ Real Time System (Biorad, Missisauga, 
Canada) was used. The cycling conditions were as follows: reverse transcription for 10 
minutes at 50˚C, initial PCR activation for 5 minutes at 95˚C, and two-step cycling which 
consisted of denaturation for 10 seconds at 95˚C and then combined annealing and 
extension for 30 seconds at 60˚C. The two-step cycling was repeated for a total of 40 
cycles. A melting curve analysis was performed at the end to ensure primer specificity.  
Changes in gene expression were determined using the ∆(∆Ct) method. ∆Ct values were 
generated for each sample by normalizing the Ct value of a gene of interest to the Ct 
value of the housekeeping gene S12. The ∆Ct values for control treatments were 
averaged to generate a mean control ∆Ct value. The ∆Ct for all samples was then 
normalized to this mean control ∆Ct, generating a ∆(∆Ct) value. Fold changes in gene 
expression were calculated by using the equation 2-∆(∆Ct). For knockout and wildtype PCR 
data, ∆(∆Ct) values were calculated by normalizing all samples to the meal ∆Ct value of 
wildtype controls.  
2.7 Cell death assay  
Cell death assays were performed using the nuclear stain Hoechst 33342 (10 µg/mL; 
Invitrogen, #H1399). Following appropriate treatment times, cells plated in 4-well dishes 
were fixed with 4% PFA for 30 minutes and then washed with 1 x PBS 3 times. The 
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second wash included Hoechst 33342 diluted 1:1000 in 1 x PBS. The stain was incubated 
for 10 minutes at room temperature in the dark. Fixed and stained cells were stored in 1 x 
PBS. Images of the cells were captured at 20x magnification on an Olympus IX70 
microscope. A CCD camera (Q-imaging, Burnaby, BC, Canada) and Northern Eclipse 
software (Empix imaging, Mississauga, ON, Canada) were used to capture images. Five 
separate fields were captured per well. Images were counted using ImageJ software with 
Fiji plugins (ImageJ, National Institutes of Health, Maryland, USA). Apoptotic nuclei as 
well as total nuclei were counted for each image and counts were averaged per well. 
Nuclei were manually counted based on their morphology. Live cells show a diffuse 
pattern of staining, while apoptotic cells have condensed, bright, and sometimes 
fragmented patterns of staining. Percent apoptotic nuclei were calculated for each well 
and counts for each treatment were averaged.  
2.8 Caspase-3 activity assay  
Caspase activity assays were performed using protein samples extracted in caspase lysis 
buffer. The lysis buffer stock contained 10 mM Hepes (Fisher Bioreagents, #BP299-500), 
1 mM KCl, 1.5 mM MgCl2, and 10% glycerol diluted in ddH2O. The following reagents 
were added fresh before use: 5 µg/mL Aproptin+, 2 µM/mL Leupeptin, 0.2 mg/mL 
PMSF, 0.1% NP40, and 1 µM DTT. Treated cells had their media aspirated and were 
washed with 1 x PBS before adding caspase cell lysis buffer directly to the dishes. Cells 
were scraped and transferred to 1.5 mL microcentrifuge tubes and incubated on ice for 30 
minutes. Lysates were centrifuged at 12,000 x g for 15 minutes at 4˚C. The supernatant 
was collected and transferred to a fresh, labelled tube. Protein samples were stored at -
80˚C. Protein concentration was determined by BCA assay as described above.  
Caspase-3 activity was measured using fluorescence generated by the cleavage of the 
substrate Ac-DEVD-AFC (Biomol, #P-409). Caspase activity buffer was composed of 
ddH2O supplemented with 25 mM Hepes, 10 mM DTT, 10% sucrose, 0.1% CHAPS 
(Roche, #10810118001), and 15 µM Ac-DEVD-AFC. Activity buffer was added to an 
opaque 96-well plate along with 0.5 µg of caspase protein per well, plated in duplicates.  
Fluorescence was measured every 20 minutes for 2 hours on a SpectraMax M5 multi-
mode microplate reader (Molecular Devices), with excitation 400 nm and emission 505 
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nm. Fluorescence was measured in arbitrary fluorescence units (AFU). Fold change in 
caspase activity was calculated by normalizing AFU values across treatments and 
genotypes to the mean AFU of wildtype controls.  
2.9 Fluorescent immunocytochemistry  
Following appropriate treatment times, primary cortical neurons plated on 12 mm glass 
cover slips (VWR, #48366-251) in 4-well dishes were fixed with 4% PFA for 30 minutes. 
Cells were permeabilized with ice-cold methanol for 5 minutes, and then washed for 5 
with 1 x PBS three separate times. Blocking in 2% BSA in 1 x PBS was performed for 
one hour at room temperature. The cells were then incubated with primary antibody 
targeting cytochrome C (Invitrogen, #338200) diluted 1:200 in blocking solution 
overnight at 4˚C. The next day, cells were washed with 1 x PBS three times and were 
incubated with AlexaFluorÒ 488 wavelength secondary antibody (Invitrogen, #A11059) 
diluted 1:500 in blocking solution for 2 hours at room temperature. The cells were 
washed with 1 x PBS and stained with Hoechst 33342 diluted 1:1000 in 1 x PBS for 10 
minutes. The coverslips were mounted onto glass microscope slides (VWR, #48311-600) 
using ProLongÔ Gold mounting glue (Invitrogen, #P36930). Images were taken using 
the EVOS Imaging System (ThermoFisher). ImageJ with Fiji plugins (ImageJ, National 
Institutes of Health, Maryland, USA) was used to quantify images and determine the 
amount of cytochrome C-positive cells in each field, expressed as a percentage of total 
cells. Images were manually counted for neurons showing retained cytochrome C signal.  
2.10 Data analysis 
Data are reported as mean ± standard error of the mean (SEM). Statistical analyses 
performed were ordinary one-way and two-way ANOVA with Tukey and Sidak post-hoc 
tests. GraphPad Prism version 8.2.0 for Mac (GraphPad Software, La Jolla, California, 
USA) was used to perform statistical testing. Statistical significance was set as p < .05.  
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Chapter 3  
3 Results 
ATF4 protein is increased in response to various cellular stressors, including endoplasmic 
reticulum stress. Thapsigargin (TG) was used to reliably induce ER stress and the ISR, 
leading to increases in endogenous ATF4 levels. TG increases cytosolic calcium 
concentrations by inhibiting calcium ATPase pumps and leads to ER stress (Lytton, 
Westlin, & Hanley, 1991). Previously, our lab has shown that TG treatment induces large 
increases in ATF4 protein levels and leads to apoptosis in an ATF4-dependent manner 
(Galehdar et al., 2010). Therefore, TG was used as a reliable inducer of the ISR and 
ATF4 protein in this study.  
3.1 Amyloid-b activates the ISR in vitro  
Firstly, we wanted to confirm that our preparation of oligomeric amyloid-b activated the 
integrated stress response and increased ATF4 protein levels in vitro. Neurons were 
treated for 6, 12, or 24 hours with 1 µM amyloid-b, 12 hours with 1 µM TG, or untreated 
(UT). Following appropriate treatment times, protein was isolated, processed, and run on 
an SDS polyacrylamide gel (Figure 3.1A). Once imaged, densitometric measurements 
were taken and protein bands were normalized to calculate changes in ATF4 protein 
expression relative to controls (Figure 3.1B). ATF4 protein was increased more than six-
fold following 6 hours of Ab, 12 hours of Ab, and 12 hours of TG (* p < .05; ** p < .01; 
n ≥ 4). Initially, ATF4 might be activated in an effort to mitigate neuronal stress, however 
prolonged activation may exacerbate the stress (Pitale et al., 2017). We can conclude that 
amyloid-b treatment does activate the ISR and result in a sustained increase in ATF4 
protein levels.  
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Figure 3.1. Oligomeric amyloid-b induces ATF4 expression. Primary cortical neurons 
were treated with oligomeric amyloid-b for 6, 12, or 24 hours, 1 µM thapsigargin for 12 
hours, or left untreated. Protein was then extracted and run on SDS-PAGE gels and 
probed for ATF4 protein. A) a representative blot of amyloid-b-induced ATF4 
expression. B) Densitometric measurements were taken and data is presented as mean ± 
SEM of ATF4 fold change relative to control (n ≥ 4). A one-way ordinary ANOVA and 
Sidak multiple comparisons tests demonstrated a significant increase in ATF4 protein 
expression following 6 and 12 hours of amyloid-b and 12 hours of thapsigargin (* p < 
.05; ** p < .01).  
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3.2 Amyloid-b increases pro-apoptotic gene expression  
Next, we wanted to investigate if the amyloid-b-induced increase in ATF4 expression 
resulted in increased ATF4 activity. ATF4 can modulate the expression of many target 
genes through its activity as a transcription factor (Baird & Wek, 2012; Wortel et al., 
2017). To study ATF4 transcriptional activity, we chose four mRNA transcripts that have 
been suggested to favour pro-apoptotic cellular outcomes: CHOP, Trib3, Gadd45a, and 
4eBP1. Previously, it has been shown that CHOP is induced following ER stress and 
leads to apoptosis through the BCL-2 protein family (Galehdar et al., 2010). Ohoka et al. 
demonstrated that ATF4 and CHOP activate the Trib3 promoter and Trib3 leads to ER 
stress-induced apoptosis (Ohoka et al., 2005). Growth arrest and DNA damage-inducible 
protein 45a (GADD45a) has been shown to be elevated in response to excitotoxicity in a 
mouse hippocampal cell line, as well as play a role in mitochondrial-dependent apoptosis 
by interacting with BCL-2 family members (Choi, Kang, Fukui, & Zhu, 2011; Tong et 
al., 2005). Eukaryotic initiation factor 4E-binding protein 1 (4eBP1) binds to and inhibits 
eIF4E, a second regulatory hub for the initiation of cap-dependent protein translation 
(Beugnet, Wang, & Proud, 2003; Gingras, Raught, & Sonenberg, 2002; Hay & 
Sonenberg, 2004; X. M. Ma & Blenis, 2009). Lastly, a microarray previously performed 
in our lab demonstrated the upregulation of these transcripts in response to ER stress 
(Cregan Lab, unpublished). Taken together, these transcripts have been shown to be 
involved in apoptosis and protein translation, therefore we wanted to further investigate 
the expression of these transcripts following amyloid-b treatment.  
Primary cortical neurons were treated with 1 µM amyloid-b for 6 hours, 12 hours, or 24 
hours, 1 µM TG for 12 hours, or untreated. Once RNA was isolated, quantitative real-
time PCR (qRT-PCR) was performed. Data are reported as fold change relative to 
untreated controls (n ≥ 5). CHOP expression was increased more than three-fold 
following all treatments with amyloid-b and close to six-fold following TG treatment 
(Figure 3.2A). Expression of Trib3 (Figure 3.2B) and Gadd45 (Figure 3.2C) were 
induced more than 3-fold following Ab treatment for 12 and 24 hours, and more than 4-
fold following treatment with TG. 4eBP1 expression was significantly increased more 
than 4-fold following 12 hours of Ab and TG treatments (Figure 3.2D). Oligomeric 
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amyloid-b therefore induces the sustained expression of pro-apoptotic genes (* p < .05; 
** p < .01; *** p < .001; **** p < .0001).  
3.3 Amyloid-b induces neuronal apoptosis 
As mentioned earlier, prolonged activation of the ISR, and prolonged elevations in ATF4 
levels can lead to apoptosis (Galehdar et al., 2010; Lange et al., 2008). Following 24 
hours and 48 hours of amyloid-b treatment, a nucleic stain was performed to examine 
whether our AD-like paradigm culminated in neuronal apoptosis (Figure 3.3A). Control 
and amyloid-b-treated neurons were fixed and stained using a Hoechst stain (n = 5). A 
significant increase in apoptotic nuclei following 24 hours (41.7% ± 2.7) and 48 hours 
(63.5% ± 1.8) of Ab treatment was found, compared to control levels at 48h (26.1% ± 
5.6; * p < .05; **** p < .0001). Additionally, there is a significant increase in apoptosis 
between 24 hours and 48 hours of amyloid-b treatment (**p < .01). Neuronal apoptosis 
was greatest following 48 hours of amyloid-b treatment (Figure 3.3B). Therefore, 
oligomeric Ab increased ATF4 protein levels, increased the expression of pro-apoptotic 
transcripts, and induced apoptotic cell death. 
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Figure 3.2. Amyloid-b induces pro-apoptotic gene expression. Primary cortical 
neurons were treated with 1 µM oligomeric amyloid-b for 6, 12, or 24 hours, 1 µM TG 
for 12 hours or left untreated. RNA was isolated and probed for multiple reported pro-
apoptotic genes using qRT-PCR. Genes probed were: A) CHOP, B) Trib3, C) Gadd45a, 
and D) 4eBP1. Amyloid-b and TG-treated neurons showed robust increases in apoptotic 
gene expression as analyzed by one-way ordinary ANOVA and Sidak post-hoc tests (* p 
< .05; ** p < .01; *** p < .001; **** p < .0001). Data shown are mean ± SEM of mRNA 
fold changes relative to untreated controls (n ≥ 5).  
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Figure 3.3. Oligomeric amyloid-b induces neuronal apoptosis. Primary cortical 
neurons were treated with or without 1 µM Ab for 24 and 48 hours prior to fixation and 
nuclear Hoechst staining. A) Representative images showing nuclear morphology 
following 24 or 48 hours of amyloid-b or control treatments. B) Apoptotic and total 
nuclei per treatment were counted and expressed as a percentage. Data shown are mean ± 
SEM of the percentage of apoptotic nuclei (n = 5). A two-way ordinary ANOVA and 
Tukey post-hoc tests revealed a significant increase in apoptotic following 24 hours and 
48 hours of amyloid-b treatment (* p < .05; **** p < .0001). Apoptosis was also 
significantly increased between 24 and 48 hours of Ab treatment (** p < .01). 
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3.3.1 Amyloid-b-induced toxicity is sequence specific 
In order to confirm that amyloid-b-induced toxicity is specific to its amino acid sequence, 
we utilized a scrambled peptide sequence of Ab. We probed for changes in ATF4 protein 
levels and apoptotic cell death. Treatment with 1 µM Ab scrambled peptide for 12 hours 
did not increase ATF4 protein levels compared to controls (Figure 3.4A; p > .05; n = 5). 
Treatment with 1 µM oligomeric amyloid-b for 12 hours induced a significant increase in 
ATF4 protein expression compared to both untreated and scrambled Ab treatments (* p < 
.05; Figure 3.4B). A Hoechst stain was performed 48 hours-post treatments with control, 
1 µM Ab scrambled peptide, and 1 µM Ab (n = 3; Figure 3.4C). Apoptosis was increased 
following Ab treatment (66.2% ± 12) compared to both UT (32.9% ± 6.4) and scrambled 
Ab (34.3% ± 7.1; * p < .05; Figure 3.4D). There was no significant difference in cell 
death between UT and scrambled Ab groups (p > .05). Therefore, we concluded that 
amyloid-b-induced toxicity is specific to its amino acid sequence.  
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Figure 3.4. Scrambled amyloid-b does not induce cellular stress. Primary cortical 
neurons were treated with 1 µM Ab, 1 µM Ab Scram or control-treated for 12 hours prior 
to protein analysis. A) Protein lysates were separated on SDS-PAGE gels and probed for 
ATF4. B) Scrambled amyloid-b-treated neurons showed no difference in ATF4 protein 
expression compared to untreated controls (p > .05). Ab-treated neurons showed 
significant induction of ATF4 compared to both untreated and scramble-treated neurons 
(* p < .05). An ordinary one-way ANOVA with Sidak multiple comparisons was 
performed to determine any differences in ATF4 expression between groups. Data 
reported are mean ± SEM of fold changes in ATF4 expression relative to control (n = 5). 
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C) Representative Hoechst stain images of untreated, Ab scram-treated, and Ab-treated 
neurons treated for 48 hours. D) Apoptotic nuclei are expressed as a percentage and 
presented as mean ± SEM (n = 3). An ordinary one-way ANOVA and Sidak post-hoc 
tests revealed a significant increase in apoptotic death following 48 hours of Ab 
treatment compared to untreated and Ab scrambled-treated neurons (* p < .05). There 
were no significant differences in apoptotic death between UT and Ab Scram neurons. 
 
  
38 
 
3.4 ATF4-deficiency attenuates pro-apoptotic gene 
expression 
Since amyloid-b treatment induced the expression of ATF4 protein and pro-apoptotic 
genes, culminating in apoptosis, we next investigated if deleting ATF4 from these 
neurons protects against Ab-induced toxicity. ATF4 heterozygous (ATF4+/-) mice were 
bred to generate ATF4 wildtype (ATF4+/+; WT) and ATF4 knockout (ATF4-/-; KO) 
littermates. ATF4+/+ (n = 9) and ATF4-/- (n = 5) cortical neurons were treated with and 
without 1 µM amyloid-b for 12 hours and RNA was isolated. We probed for changes in 
the mRNA expression of CHOP, Trib3, Gadd45a, and 4eBP1 through qRT-PCR. Ab-
treated wildtype neurons showed an eleven-fold increase in CHOP expression (Figure 
3.5A), a fourteen-fold increase in Trib3 expression (Figure 3.5B), and an eight-fold 
increase in both Gadd45a (Figure 3.5C) and 4eBP1 expression (Figure 3.5D) compared 
to untreated wildtype controls (** p < .01; **** p < .0001). In Ab-treated ATF4 
knockout neurons, pro-apoptotic gene expression was attenuated (** p < .01; *** p < 
.001; **** p < .0001). No significant difference between untreated ATF4+/+ and untreated 
ATF4-/- groups were found for all four genes probed (p > .05). There was also no 
statistical difference between untreated WT and untreated KO neurons compared to Ab-
treated knockout neurons (p > .05). The attenuation of pro-apoptotic gene expression in 
knockout neurons treated with amyloid-b demonstrates the responsiveness of these 
transcripts to the presence of ATF4.  
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Figure 3.5. Pro-apoptotic gene expression is attenuated in ATF4-deficient neurons. 
ATF4 wildtype and knockout neurons were treated with and without 1 µM amyloid-b for 
12 hours prior to RNA isolation. qRT-PCR was performed probing for the following 
genes: A) CHOP, B) Trib3, C) Gadd45a, and D) 4eBP1. Amyloid-b robustly induced the 
expression of all four pro-apoptotic genes in ATF4 +/+ neurons, which was attenuated in 
Ab-treated ATF4-/- neurons (** p < .01; *** p < .001; **** p < .0001). An ordinary two-
way ANOVA and Tukey post-hoc tests were performed to determine statistical 
significance. Data are reported as mean ± SEM of mRNA fold changes relative to 
untreated wildtype controls (ATF4+/+ n = 9; ATF4-/- n = 5).   
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3.5 Apoptosis is attenuated in ATF4-deficient neurons 
We next investigated apoptotic death in ATF4 wildtype and knockout neurons following 
control and amyloid-b treatments. A Hoechst stain was used to identify apoptotic nuclei 
following 24 hours and 48 hours of treatment (Figure 3.6A; ATF4+/+ n = 7; ATF4-/- n = 
6). Cell death was significantly increased in ATF4+/+ neurons treated with amyloid-b 
(42.5% ± 4.8) for 24h compared to ATF4+/+ controls (21.3% ± 1.5; *** p < .001). 
Apoptosis was attenuated in ATF4 knockout neurons treated with Ab for 24h (23.2% ± 
2.0; ** p < .01; Figure 3.6B). The same pattern was observed in neurons treated for 48h, 
with the increase in cell death even greater in ATF4+/+ neurons treated with Ab (65.6% ± 
3.2; **** p < .0001; Figure 3.6C). Neuronal apoptosis in ATF4 knockout neurons treated 
with amyloid-b was attenuated to control levels regardless of the length of treatment (p > 
.05). Therefore, ATF4 is necessary for amyloid-b-induced apoptosis.  
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Figure 3.6. ATF4 is necessary for amyloid-b-induced apoptosis. ATF4 wildtype and 
knockout cortical neurons were treated with and without 1 µM amyloid-b for 24 and 48 
hours prior to being fixed and Hoechst stained. A) Representative images demonstrated 
increased apoptotic nuclear morphology in wildtype neurons treated with amyloid-b at 
both time points. B) Following 24 hours of amyloid-b, wildtype neurons displayed a 
significant increase in apoptotic nuclei compared to wildtype controls (*** p < .001; n = 
7). ATF4-deficient neurons (n = 6) displayed significantly attenuated levels of apoptotic 
nuclei (** p < .01). C) ATF4 wildtype neurons treated with amyloid-b for 48 hours 
showed more robust levels of apoptotic nuclei compared to wildtype controls (**** p < 
.0001). ATF4-deficient neurons had attenuated levels of apoptosis (**** p < .0001). 
Ordinary two-way ANOVAs and Tukey post-hoc tests were performed. Data are reported 
as mean percent apoptotic nuclei ± SEM.  
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3.6 PUMA mediates neuronal apoptosis in an ATF4-
dependent manner 
In an effort to elucidate the apoptotic pathway induced by amyloid-b, we focused on the 
BCL-2 protein family. More specifically, we focused on p53 upregulated mediator of 
apoptosis (PUMA), which is a BH3-only domain protein (Youle & Strasser, 2008). 
PUMA interacts with and inhibits the anti-apoptotic Bcl-2 family members, thus 
promoting apoptosis. Interaction of PUMA with the pro-apoptotic BCL-2 protein 
member BAX leads to outer mitochondrial membrane permeabilization and release of 
pro-apoptotic molecules. Subsequently, caspases are activated and induce apoptosis. 
Previously, our lab has demonstrated that PUMA can be activated through the induction 
of endoplasmic reticulum stress and oxidative stress (Galehdar et al., 2010; Steckley et 
al., 2007). Therefore, we hypothesized that amyloid-b induces apoptosis in an ATF4- and 
PUMA-dependent manner. 
3.6.1 Amyloid-b induces ATF4-dependent PUMA expression 
We first examined the levels of PUMA transcript in ATF4+/+ and ATF4-/- neurons 
following 12h of amyloid-b treatment. ATF4 wildtype and knockout neurons showed no 
significant difference in PUMA expression under control conditions (Figure 3.7; p > .05). 
Following 12h of Ab treatment, wildtype neurons displayed a large increase in PUMA 
expression compared to wildtype controls (*** p < .001). PUMA levels were attenuated 
in ATF4 knockout neurons (** p < .01) and treated ATF4-/- neurons showed no difference 
in expression compared to ATF4-/- controls (p > .05). We concluded that PUMA 
expression is induced in an ATF4-dependent manner following amyloid-b treatment.  
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Figure 3.7. PUMA expression is attenuated in ATF4-deficient neurons. ATF4 
wildtype and knockout neurons were treated with and without 1 µM amyloid-b for 12 
hours prior to RNA isolation. qRT-PCR was performed probing for changes in PUMA 
expression. Amyloid-b treatment increased PUMA expression in ATF4 +/+ neurons, 
which was attenuated in Ab-treated ATF4-/- neurons (** p < .01; *** p < .001; ****). An 
ordinary two-way ANOVA and Tukey post-hoc tests were performed to determine 
statistical significance. Data are reported as mean ± SEM of mRNA fold changes relative 
to untreated wildtype controls (ATF4+/+ n = 9; ATF4-/- n = 5). 
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3.6.2 Caspase-mediated apoptosis is attenuated in PUMA-
deficient neurons 
Next, we investigated whether PUMA is required to mediate amyloid-b-induced 
apoptosis. Increased expression and activity of PUMA induces the intrinsic apoptotic 
pathway and the release of soluble pro-apoptotic molecules from the mitochondrial 
intermembrane space (Willis et al., 2007). Cytochrome C is the best studied of these 
proteins, and its release from the mitochondria activates the formation of an apoptosome 
and the activation of caspases (Youle & Strasser, 2008). Cytochrome C serves as a 
marker of PUMA-dependent apoptosis. Using immunofluorescent staining, we 
investigated the retention of cytochrome C in PUMA+/+ and PUMA-/- neurons treated 
with and without 1 µM amyloid-b for 48 hours (n = 3; Figure 3.8A). The percentage of 
cytochrome C-positive cells was significantly attenuated in PUMA+/+ neurons (22.5% ± 
2.6; * p < .05; ** p < .01) compared to both PUMA+/+ untreated neurons (64.0% ± 11.3) 
and PUMA-/- amyloid-b-treated neurons (57.9% ± 4.5; Figure 3.8B). Additionally, the 
same PUMA-/- amyloid-b treated neurons had a significantly greater percentage of 
apoptotic nuclei (68.6% ± 6.9; ** p < .01) compared to wildtype controls (24.9% ± 7.8) 
and PUMA-deficient amyloid-b treated neurons (21.4% ± 5.2; Figure 3.8C), measured 
using Hoechst stain. 
Following our cytochrome C results, we investigated caspase activity in PUMA+/+, 
PUMA+/- and PUMA-/- littermates. We investigated the activity of caspase-3, which lies 
downstream of PUMA and cytochrome C. Caspase-3 activation leads to irreversible 
commitment to apoptosis. A fluorescence-based caspase activity assay was performed 
using wildtype and heterozygous neurons (PUMA+/0; n = 7) compared to PUMA 
knockout neurons (n = 8). All neurons underwent treatment with and without amyloid-b 
for 36 hours. No significant differences in caspase activity at baseline between genotypes 
were found (p > .05). Following amyloid-b treatment, PUMA+/0 neurons showed a robust 
increase in caspase activity compared to untreated controls (** p < .01). Additionally, 
there was attenuation of caspase activity in Ab-treated PUMA-/- neurons (* p < .05). 
Therefore, our cytochrome C and caspase activity assays determined that amyloid-b 
induces neuronal death in a PUMA-dependent manner. 
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Figure 3.8. Amyloid-b-induced cell death occurs in a PUMA-dependent manner.  A) 
PUMA+/+ and PUMA-/- neurons were treated with and without amyloid-b for 48 hours 
prior to being fixed and immunostained for cytochrome C. Nuclei were visualized using 
Hoechst stain. B) PUMA+/+ neurons had a significant reduction in cytochrome C-positive 
cells, which is indicative of mitochondrial-dependent apoptosis (** p < .01). The 
percentage of cytochrome C positive cells in PUMA+/+ neurons was attenuated compared 
to amyloid-b treated PUMA-deficient neurons (* p < .05). C) Apoptosis was significantly 
increased in Ab-treated wildtype neurons compared to wildtype controls and Ab-treated 
knockout neurons (** p < .01). D) Caspase-3 activity was measured using a substrate that 
fluoresces when cleaved. Arbitrary fluorescence units (AFUs) were recorded and 
normalized to the mean AFU of PUMA+/0 samples, thereby generating a fold change 
value relative to control. Caspase-3 activity was significantly increased following 
amyloid-b treatment in PUMA+/0 neurons (n = 7), compared to both untreated PUMA+/0 
neurons (** p < .01) and amyloid-b-treated PUMA-deficient neurons (* p < .05; n = 8). 
Two-way ordinary ANOVA with Tukey post-hoc tests were performed for each data set 
to determine statistically significant differences between treatment groups and genotypes. 
Data reported are mean ± SEM of the percent of cytochrome C-positive cells, the percent 
of apoptotic nuclei, and the relative AFU of caspase-3 activity. 
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Chapter 4  
4 Discussion 
ATF4 is a member of the integrated stress response and its translation is paradoxically 
enhanced during periods of cellular stress when global protein translation is reduced 
(Harding et al., 2000). It is a bZIP transcription factor that modulates the expression of 
many stress-responsive genes involved in cellular processes such as autophagy, amino 
acid synthesis, and apoptosis (B’Chir et al., 2013; Harding et al., 2003). The wide range 
of transcription factors that ATF4 can heterodimerize with determine its transcriptional 
selectivity and the outcome of ISR signaling (Hai & Curran, 1991; Karpinski et al., 
1992). Prolonged activation of the ISR and elevated levels of ATF4 have been shown to 
favour pro-death outcomes, specifically in neurons (Galehdar et al., 2010; Lange et al., 
2008; Wortel et al., 2017). It has been well-documented in Alzheimer’s disease and 
Alzheimer’s disease paradigms that amyloid-b induces high levels of neuronal stress 
(Deshpande et al., 2006). In the present study, we aimed to investigate the relationship 
between amyloid-b, ATF4, and neuronal cell death. We provide evidence that (a) 
amyloid-b induces ATF4 expression and neuronal death, that (b) amyloid-b-induced 
death requires ATF4, and that (c) amyloid-b induces death through a PUMA-dependent 
process in the presence of ATF4.  
4.1 Oligomeric Amyloid-b induces ATF4 expression and 
apoptosis in neurons 
Previously, it has been demonstrated that amyloid-b induces high levels of neuronal 
stress in vitro and in post mortem samples from Alzheimer’s disease patients (Baleriola et 
al., 2014; T. Ma et al., 2013). Markers of oxidative and endoplasmic reticulum stress 
have been measured in these samples. In the APP-PS1 mouse model of Alzheimer’s 
disease, significant increases in the levels of phosphorylated eIF2a were found in the 
hippocampus and prefrontal cortex (Ma et al., 2013). Elevated levels of ATF4 were found 
in the hippocampi of these animals. In human post mortem samples, high levels of 
phosphorylated eIF2a were found in the hippocampus, mirroring the findings from the 
animal study (Ma et al., 2013). ATF4-positive cell bodies and axons were also found at a 
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higher frequency in the hippocampi of AD patients compared to age-matched controls 
(Baleriola et al., 2014). Chronic cellular stress results in the prolonged activation of the 
ISR and elevated levels of ATF4. Prolonged increases of ATF4 expression have been 
shown to favour pro-apoptotic cellular outcomes in neurons (Galehdar et al., 2010; Lange 
et al., 2008).  
In the present study, primary cortical neurons extracted from embryonic mice were 
treated with oligomeric amyloid-b. We found that amyloid-b treatment induced a 
sustained increase in ATF4 protein expression, as well as a sustained increase in pro-
apoptotic gene expression. We probed for changes in the mRNA expression of CHOP, 
Trib3, Gadd45a, and 4eBP1. CHOP is a well-studied pro-apoptotic target gene of ATF4. 
In addition to CHOP being a target gene of ATF4 transcriptional regulation, CHOP is 
also able to heterodimerize with ATF4 and modulate the expression of many more genes. 
Research suggests that ectopic CHOP overexpression is sufficient to induce apoptotic 
death (Matsumoto, Minami, Takeda, Sakao, & Akira, 1996). Previous studies have found 
that Trib3, a pseudokinase, promotes apoptosis in neuronal cells (Aime et al., 2015; 
Lange et al., 2008; Ohoka et al., 2005). Trib3 expression is induced following both 
oxidative and endoplasmic reticulum stress, as well as in cellular models of Parkinson’s 
disease. ATF4 and CHOP heterodimers have been shown to activate the Trib3 promoter 
and induce expression (Ohoka et al., 2005). Gadd45a is a pro-death, stress-inducible 
protein. Research demonstrates that Gadd45a promotes apoptosis by interacting with the 
BCL-2 protein family (Tong et al., 2005). Inducible expression of Gadd45a in the 
absence of stress is sufficient to induce apoptosis. 4eBP1 is a translational repressor of 
the eIF4E complex involved in identifying the 5’ cap of mRNA transcripts (Beugnet et 
al., 2003). Phosphorylation of 4eBP1 releases it from eIF4E and allows protein initiation 
to proceed. As mentioned previously, Alzheimer’s disease can be characterized by 
aberrant cell death and synaptic dysfunction. De novo protein synthesis is essential to the 
maintenance of long-term potentiation, while cellular stress leads to a reduction in global 
protein translation through the ISR and phosphorylation of eIF2a. The increase in 4eBP1 
expression seen in response to amyloid-b provides a second explanation for synaptic 
dysfunction in AD by inhibiting the translation of newly transcribed mRNA transcripts.  
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The results of the present study provide support that sustained upregulation of ATF4 
favours pro-apoptotic cellular outcomes. We found a prolonged increase in ATF4 
expression following treatment with amyloid-b. Pro-apoptotic gene expression was 
robustly increased by treatment with Ab. Following 24 and 48 hours of amyloid-b 
treatment, primary cortical neurons showed significantly elevated proportions of 
apoptotic nuclei compared to control-treated neurons. The number of apoptotic nuclei 
was even greater following 48 hours of amyloid-b treatment compared to 24 hours of 
treatment. In addition, toxicity induced by amyloid-b is specific to its amino acid 
sequence, as evaluated in the experiments using a scrambled version of the amyloid-b 
peptide. The scrambled amyloid-b peptide did not induce the expression of pro-apoptotic 
genes and did not induce apoptosis in primary cortical neurons. Therefore, treatment with 
amyloid-b resulted in sustained ATF4 expression, increased transcription of stress-
responsive pro-apoptotic genes, and apoptosis.  
4.2 ATF4 is necessary for amyloid-b-induced neuronal 
death 
Following our experiments that determined oligomeric amyloid-b induces ATF4 
expression and leads to apoptosis, we wanted to further investigate the role that ATF4 
plays in amyloid-b-induced neuronal death. Our lab has previously shown that ATF4 
promotes neuronal apoptosis in endoplasmic reticulum stress paradigms (Galehdar et al., 
2010). Tunicamycin and thapsigargin, potent inducers of ER stress, induced apoptosis in 
an ATF4-dependent manner. ATF4-deficient neurons were more resistant toward ER-
stress induced apoptosis (Galehdar et al., 2010). In the present study, ATF4-deficient 
primary cortical neurons were treated with and without amyloid-b. The same pro-
apoptotic genes were probed for changes in expression in wildtype and knockout 
neurons. Pro-apoptotic gene expression was attenuated in an ATF4-dependent manner. 
This provides evidence that CHOP, Trib3, Gadd45a, and 4eBP1 are ATF4-responsive 
following treatment with amyloid-b. ATF4-deficient neurons were also protected against 
amyloid-b-induced apoptosis. Following both 24 and 48 hours of amyloid-b treatment, 
ATF4 knockout neurons had attenuated apoptosis. Cell death experiments, together with 
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the results demonstrating attenuated pro-apoptotic gene expression in knockout neurons, 
led us to the conclusion that ATF4 is necessary for amyloid-b-induced neuronal 
apoptosis. This has important implications for Alzheimer’s disease, as aberrant cell death 
occurs as the disease progresses.  
4.3 Amyloid-b-induced death occurs through ATF4-
mediated upregulation of PUMA 
Previous work from our lab has demonstrated that BCL-2 family proteins play critical 
roles in the induction of oxidative stress and ER stress-induced apoptosis. The BCL-2 
family is composed of pro-survival and pro-apoptotic proteins that interact to determine 
cell fate. PUMA is a BH3-only pro-apoptotic member of the BCL-2 family that has been 
extensively studied in our lab. PUMA was initially thought to be p53-dependent, however 
it is now known that it can be activated by both p53-dependent and -independent 
mechanisms (Galehdar et al., 2010). PUMA can be activated by endoplasmic reticulum 
and oxidative stress (Galehdar et al., 2010; Steckley et al., 2007). ER stress-induced 
PUMA expression occurs in an ATF4-dependent manner (Galehdar et al., 2010). In the 
present study we wanted to investigate the role that PUMA plays in amyloid-b-induced 
neuronal death. 
Following treatment with amyloid-b, ATF4 wildtype neurons displayed a significant 
increase in PUMA mRNA expression. mRNA levels were attenuated in ATF4-deficient 
neurons. Next, primary cortical neurons were extracted from PUMA wildtype, 
heterozygous, and knockout neurons. In the mitochondrial apoptotic pathway, following 
activation, PUMA interacts indirectly or directly with other pro-apoptotic Bcl-2 members 
(Steckley et al., 2007; Willis et al., 2007). PUMA has been shown to activate the pro-
apoptotic member BAX, which then translocates to the outer mitochondrial membrane. 
BAX causes permeabilization of the outer membrane and the release of soluble pro-
apoptotic molecules into the cytoplasm, of which Cytochrome C is very well 
characterized (Kuwana et al., 2002). Cytochrome C release triggers formation of the 
apoptosome and the cleavage and subsequent activation of caspases (Li et al., 1997; 
Youle & Strasser, 2008). We investigated the retention of cytochrome C in PUMA 
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wildtype and knockout neurons following amyloid-b treatment for 48 hours. PUMA+/+ 
neurons displayed a significant reduction in cytochrome C positive cells post-treatment, 
as well as a significant increase in the percentage of apoptotic nuclei. PUMA-deficient 
neurons showed preservation of cytochrome C staining and an attenuation of apoptosis. A 
caspase-3 activity assay was performed using PUMA+/0 and PUMA-/- neurons following 
treatment with amyloid-b for 36 hours. We found that the presence of even one allele of 
the PUMA gene was sufficient to induce robust caspase activity following amyloid-b 
treatment. PUMA-deficient neurons displayed attenuated caspase-3 activity, which 
compliments the cytochrome C data found previously. PUMA-deficient neurons have 
retained cytochrome C within mitochondria, low activity of caspase-3, and attenuated 
apoptosis. Therefore, amyloid-b-induced neuronal death occurs in a PUMA-dependent 
manner in the presence of ATF4. 
4.4 Implications of ATF4 in Alzheimer’s disease 
The present study highlights the important role that ATF4 has under an Alzheimer’s 
disease-like paradigm. Excessive neuronal death and synaptic dysfunction are two 
cellular hallmarks that characterize Alzheimer’s disease. ATF4 lies at the intersection 
between protein translation mechanisms and apoptosis, the latter being investigated in 
this study. Moving forward, it is important to continue elucidating the exact cascade that 
leads from extracellular amyloid-b to ATF4 expression, and lastly to PUMA induction. In 
addition, future research should also focus on the role that ATF4 plays within the context 
of LTP and memory. Whole-embryo ATF4 knockout animals are not adequate for 
behavioural studies due to the developmental role of ATF4 in non-neuronal tissues. 
Brain-specific ATF4 knockout animals, or inducible brain-specific ATF4 knockout 
animals, should be used for studies of synaptic dysfunction and behaviour to limit the off-
target effects of ATF4-deficiency.  
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Chapter 5  
5 Conclusion 
Sustained upregulation of ATF4 has been shown to be pro-apoptotic in neurons, however 
the exact mechanism of ATF4-mediated death in response to amyloid-b is not fully 
understood. Previous studies have suggested a relationship between Alzheimer’s disease, 
oligomeric amyloid-b, ATF4, and neuronal death. The findings of the present study 
support this paradigm, as well as provide a link between ATF4 and neuronal apoptosis 
(Figure 5.1). We found that oligomeric amyloid-b induces neuronal apoptosis in an 
ATF4-dependent manner. Furthermore, we demonstrate that the expression of PUMA, a 
pro-apoptotic BCL-2 family member, is induced in the presence of ATF4. Amyloid-b 
induces death through the intrinsic mitochondrial apoptotic pathway, since PUMA-
deficient neurons are protected against amyloid-b-induced death. Taken together, we 
conclude that amyloid-b-induced neuronal death occurs in a PUMA-dependent manner in 
the presence of ATF4. 
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Figure 5.1. Schematic of amyloid-b-induced neuronal apoptosis. We propose that 
amyloid-b induces neuronal death through upregulation of ATF4 and subsequent 
induction of PUMA. PUMA indirectly or directly activates the pro-apoptotic protein 
BAX, which permeabilizes the outer mitochondrial membrane and releases cytochrome C 
into the cytoplasm. Cytochrome C subsequently activates caspase-3, culminating in 
apoptosis.  
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Appendices 
 
 
Appendix A: ATF4 genotyping primers 
Wildtype Forward AGCAAAACAAGACAGCAGCCACTA 
Knockout Forward ATATTGCTGAAGAGCTTGGCGGC 
Common Reverse GTTTCTACAGCTTCCTCCACTCTT 
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Appendix B: PUMA genotyping primers 
Primer 1 AGGCTGTCCCTGGGGTCATCCC 
Primer 2 GGACTGTCGCGGGCTAGACCCTCTG 
Primer 3 ACCGCGGGCTCCGAGTAGC 
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Appendix C: List of qRT-PCR primers 
Gene Forward Sequence Reverse Sequence 
4eBP1 GGGGACTACAGCACCACTC GTTCCGACACTCCATCAGAAAT 
CHOP ACAGAGGTCACACGCACATC GGGCACTGACCACTCTGTTT  
Gadd45a CTGCTGCTACTGGAGAACGAC CGACTTTCCCGGCAAAAACAAA  
PUMA CCTCAGCCCTCCCTGTCACCAG CCGCCGCTCGTACTGCGCGTTG  
S12 GGAAGGCATAGCTGCTGG CCTCGATGACATCCTTGG  
Trib3 TGCAGGAAGAAACCGTTGGAG CTCGTTTTAGGACTGGACACTT  
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